A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention

Immunomodulatory properties of histone deacetylase inhibitors represent a reasonable approach for acute graft-versus-host disease (aGVHD) prevention. We report a phase 2 trial evaluating panobinostat (PANO) administered over 26 weeks, starting on day −5 (5 mg orally 3 times a week) with tacrolimus i...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood Adv
Autori principali: Perez, Lia, Fernandez, Hugo, Kharfan-Dabaja, Mohamed, Khimani, Farhad, Betts, Brian, Mishra, Asmita, Ayala, Ernesto, Locke, Frederick L., Ochoa-Bayona, Leonel, Nieder, Michael, Pidala, Joseph, Achille, Alex, Powers, John, Sahakian, Eva, Thapa, Ram, Wang, Xuefeng, Anasetti, Claudio
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2021
Soggetti:
Transplantation
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8288668/
https://ncbi.nlm.nih.gov/pubmed/34242388
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2021004225
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi